Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patients

Published:2022-06-02 Issue:3 Volume:3 Page:815-827
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Cheng Yiming¹^ORCID,Hong Kevin²,Chen Nianhang¹,Yu Xin³,Peluso Teresa⁴,Zhou Simon¹,Li Yan¹

Affiliation:

1. Clinical Pharmacology & Pharmacometrics Bristol Myers Squibb New Jersey USA

2. Global Drug Development Bristol Myers Squibb New Jersey USA

3. Global Biometric Sciences Bristol Myers Squibb New Jersey USA

4. Global Drug Development Bristol Myers Squibb Boudry Switzerland

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.494

Reference32 articles.

1. International uniform response criteria for multiple myeloma

2. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

3. Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development

4. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

5. Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP